NeuroTherapia Receives Grant from Alzheimer’s Association for Development of First-in-Class Drug for Alzheimer’s Disease

NeuroTherapia, an early-stage clinical pharmaceutical company, announced today that it has received a grant from the Alzheimer’s Association Part the Cloud program for the development of its first-in-class drug, NTRX-07, for the treatment of Alzheimer’s disease (AD). 

Read More